<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Dev Immunol</journal-id><journal-title>Clinical and Developmental Immunology</journal-title><issn pub-type="ppub">1740-2522</issn><issn pub-type="epub">1740-2530</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pii">S1740252206000011</article-id><article-id pub-id-type="doi">10.1080/17402520600554930</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antibodies Against &#x003b2;<sub>2</sub>-Glycoprotein I Complexed With an Oxidised Lipoprotein Relate to Intima Thickening of Carotid Arteries in Primary Antiphospholipid Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ames</surname><given-names>P. R. J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alves</surname><given-names>J. Delgado</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>L. R.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gentile</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Margarita</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pizzella</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Batuca</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Scenna</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Brancaccio</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Matsuura</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Academic Department of Rheumatology</addr-line><addr-line>Leeds General Infirmary</addr-line><addr-line>Leeds</addr-line><country>UK</country></aff><aff id="aff2"><label>2</label><addr-line>Department of Pharmacology</addr-line><addr-line>Faculty of Medical Sciences</addr-line><addr-line>New University of Lisbon</addr-line><addr-line>Lisbon</addr-line><country>Portugal</country></aff><aff id="aff3"><label>3</label><addr-line>Corgenix, Inc.</addr-line><addr-line>Westminster</addr-line><addr-line>Colorado</addr-line><country>USA</country></aff><aff id="aff4"><label>4</label><addr-line>Department of Health Sciences (SpeS)</addr-line><addr-line>Molise University</addr-line><addr-line>Campobasso</addr-line><country>Italy</country></aff><aff id="aff5"><label>5</label><addr-line>Angiology and Coagulation Units Cardarelli Hospital</addr-line><addr-line>Naples</addr-line><country>Italy</country></aff><aff id="aff6"><label>6</label><addr-line>Department of Animal, Agricultural &#x00026; Environmental Sciences (SAVA)</addr-line><addr-line>Molise University</addr-line><addr-line>Campobasso</addr-line><country>Italy</country></aff><aff id="aff7"><label>7</label><addr-line>Department of Cell Chemistry</addr-line><addr-line>Graduate School of Medicine</addr-line><addr-line>Dentistry and Pharmaceutical Sciences</addr-line><addr-line>Okayama University</addr-line><addr-line>Okayama</addr-line><country>Japan</country></aff><pub-date pub-type="ppub"><month>3</month><year>2006</year></pub-date><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &#x000a9; 2006 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>To explore whether antibodies against &#x003b2;<sub>2</sub>-glycoprotein I (&#x003b2;<sub>2</sub>GPI) complexed to 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and to oxidised low-density lipoproteins (oxLDL) relate to paraoxonase activity (PONa) and/or intima media thickness (IMT) of carotid arteries in primary antiphospholipid syndrome (PAPS). As many as 29 thrombotic patients with PAPS, 10 subjects with idiopathic antiphospholipid antibodies (aPL) without thrombosis, 17 thrombotic patients with inherited thrombophilia and 23 healthy controls were investigated. The following were measured in all participants: &#x003b2;<sub>2</sub>GPI&#x02212;oxLDL complexes, IgG anti-&#x003b2;<sub>2</sub>GPI&#x02212;oxLig-1, IgG anti-&#x003b2;<sub>2</sub>GPI&#x02212;oxLDL antibodies (ELISA), PONa, (para-nitrophenol method), IMT of common carotid (CC) artery, carotid bifurcation (B), internal carotid (IC) by high resolution sonography. &#x003b2;<sub>2</sub>GPI&#x02212;oxLDL complex was highest in the control group (<italic>p</italic> &#x0003c; 0.01), whereas, IgG anti-&#x003b2;<sub>2</sub>GPI&#x02212;oxLig1 and IgG anti-&#x003b2;<sub>2</sub>GPI&#x02212;oxLDL were highest in PAPS (<italic>p</italic> &#x0003c; 0.0001). In healthy controls, &#x003b2;<sub>2</sub>GPI&#x02212;oxLDL complexes positively correlated to IMT of the IC (<italic>p</italic> = 0.007) and negatively to PONa after correction for age (<italic>p</italic> &#x0003c; 0.03). PONa inversely correlated with age (<italic>p</italic> = 0.008). In PAPS, IgG anti-2GPI&#x02212;oxLig-1 independently predicted PONa (<italic>p</italic> = 0.02) and IMT of B (<italic>p</italic> = 0.003), CC, (<italic>p</italic> = 0.03) and of IC (<italic>p</italic> = 0.04). In PAPS, PONa inversely correlated to the IMT of B, CC and IC (<italic>p</italic> = 0.01, 0.02 and 0.003, respectively). IgG anti-2GPI&#x02212;oxLig-1 may be involved in PAPS related atherogenesis via decreased PON activity.</p></abstract></article-meta></front></article> 